 Home > Medical News > Latest Medical News > AstraZeneca launches next-generation PARP inhibitors to continue Lynparza's success

AstraZeneca launches next-generation PARP inhibitors to continue Lynparza's success

 Last Update: 2021-04-18
 Source: Internet
 Author: User

Tags

regadenoson side effects

bisacodyl side effects

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Compileriver

AstraZeneca’s PARP inhibitor Lynparza has quickly become a hot-selling product by inhibiting the full healing ability of tumor cells and killing tumor cells.

At the AACR meeting, AstraZeneca announced early data on its PARP1 selective next-generation inhibitor AZD5305, hoping to emphasize the drug's follow-up and improvement opportunities for the blockbuster Lynparza.

In a set of abstracts, AstraZeneca listed the case of AZD5305, which entered phase I clinical trials in December last year, including early in vivo preclinical data as a single-agent treatment and in combination with standard treatments.

Lynparza is a PARP1/2 inhibitor, and its combined treatment range is limited due to side effects.

The DDR pathway is an ancient target for pharmaceutical manufacturers, but with the advent of PARP, it has become popular and may suppress its frustrating safety features.

Susan Galbraith, Senior Vice President and Head of Oncology Research and Development of AstraZeneca, said: “We believe this will represent cleaner safety features, stronger cell killing power and broader binding capacity in the clinic.

Article reference source:

AstraZeneca unveils next-gen PARP inhibitor, looking to follow up on success of first-gen success story Lynparza

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.